Incyte Corporation is part of the Pharmaceuticals, Biotechnology & Life Sciences sector. The company has a ESG Pulse of 0.91 which is calculated using alternative data outside of company disclosure to provide an 'outside-in' view on company ESG performance.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
ESG Pulse
ESG Pulse is ranked on a scale of -1 (negative) to +1 (good). This is the average sentiment of all items that have been classified as material ESG'
Updated on:
2022-04-12
Historical ESG Pulse
View historical company ESG pulse and compare against industry, overlay stock prices or view vs peers.
Materiality
View company ESG performance broken down by the 26 SASB topics.
Traditional ESG data doesn't give you the full picture
The old way
Reliant on company disclosure and analysts
Traditional providers such as MSCI and Sustainalytics rely on company disclosure - which happens infrequently. They employ armies of analysts to gather this data.
ESG data and scores are stale (every 6-12 months)
Low amount company coverage
ESG data is extremely expensive
ESG data is not always transparent/objective
The new way
Dynamic, real-time ESG data
Alternative data such as news, media, job postings, social media and others - allow us to extract signals from the 'outside-in' using AI and fully automated approaches.
.png)
.png)
